Allelic loss as prognostic factor in breast cancer
Utada, Y.; Emi, M.; Haga, S.; Kajiwara, T.
Nihon Rinsho. Japanese Journal of Clinical Medicine 58 Suppl: 473-477
2000
ISSN/ISBN: 0047-1852 PMID: 11026036 Document Number: 519877
Document emailed within 1 workday
Related Documents
Haase, W. 1995: Tissue CEA as a prognostic factor in patients with breast cancer Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft . 171(2): 117-118Eskelinen, M.; Lipponen, P.; Syrjänen, K. 1991: TAG 12 expression as a prognostic factor in female breast cancer Anticancer Research 11(5): 1683-1686
Foekens, J.A.; Portengen, H.; van Putten, W.L.; Trapman, A.M.; Reubi, J.C.; Alexieva-Figusch, J.; Klijn, J.G. 1989: Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer Cancer Research 49(24 Part 1): 7002-7009
Jansen, R.L.; Joosten-Achjanie, S.R.; Volovics, A.; Arends, J.W.; Hupperets, P.S.; Hillen, H.F.; Schouten, H.C. 1998: Relevance of the expression of bcl-2 in combination with p53 as a prognostic factor in breast cancer Anticancer Research 18(6a): 4455-4462
Cooney, K.A.; Wetzel, J.C.; Merajver, S.D.; Macoska, J.A.; Singleton, T.P.; Wojno, K.J. 1996: Distinct regions of allelic loss on 13q in prostate cancer Cancer Research 56(5): 1142-1145
Kozlowski, L.; Filipowski, T.; Rucinska, M.; Pepinski, W.; Janica, J.; Skawronska, M.; Poznanski, J.; Wojtukiewicz, M.Z. 2006: Loss of heterozygosity on chromosomes 2p, 3p, 18q21.3 and 11p15.5 as a poor prognostic factor in stage II and III (FIGO) cervical cancer treated by radiotherapy Neoplasma 53(5): 440-443
Bonneterre, J.; Peyrat, J.P.; Beuscart, R.; Demaille, A. 1990: Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer Cancer Research 50(21): 6931-6935
Jansen, R.L.; Hupperets, P.S.; Arends, J.W.; Joosten-Achjanie, S.R.; Volovics, A.; Hillen, H.F.; Schouten, H.C. 1998: pS2 is an independent prognostic factor for post-relapse survival in primary breast cancer Anticancer Research 18(1b): 577-582
Sheen-Chen, S.-M.; Chou, F.-F.; Hsu, W.; Huang, C.-C.; Eng, H.-L.; Tang, R.-P. 2007: Lack of prognostic value of insulin-like growth factor-1 in patients with breast cancer: analysis with tissue microarray Anticancer Research 27(5b): 3541-3544
Lajtman, Z.; Vincelj, J.; Borcić, V. 1998: Vertigo as a prognostic factor in sudden hearing loss Acta Medica Croatica: Casopis Hravatske Akademije Medicinskih Znanosti 52(2): 115-118
Ogawa, Y.; Chung, Y.S.; Nakata, B.; Takatsuka, S.; Maeda, K.; Sawada, T.; Kato, Y.; Yoshikawa, K.; Sowa, M. 1995: Clinical significance of argyrophilic nucleolar organizer regions (AgNOR) and microvessel quantitation by staining for factor VIII-related antigen as prognostic indicators in stage i breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(Suppl 1): 66-70
Rudan, I.; Skorić, T.; Rudan, N. 1994: Breast cancer prognosis. I. Prognostic factors in patients with node-negative (N0) breast cancer Acta Medica Croatica: Casopis Hravatske Akademije Medicinskih Znanosti 48(4-5): 159-163
Rudan, I.; Skorić, T.; Rudan, N. 1994: Breast cancer prognosis. II. Prognostic factors in patients with node-positive (N1-3) breast cancer Acta Medica Croatica: Casopis Hravatske Akademije Medicinskih Znanosti 48(4-5): 165-170
Tominaga, T.; Abe, O.; Izuo, M.; Isono, K.; Enomoto, K.; Nishi, M.; Fukami, A.; Muto, T.; Morioka, Y.; Watanabe, H. 1993: Correlations between estrogen receptor and prognostic factors of patients with breast cancer. the Kanto Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(14): 2171-2176
Wang, S.-l.; Li, Y.-x.; Song, Y.-w.; Wang, W.-h.; Jin, J.; Liu, Y.-p.; Liu, X.-f.; Yu, Z.-h. 2010: Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy Zhonghua Zhong Liu Za Zhi 32(7): 520-525
Penault-Llorca, F.; Jacquemier, J.; Le Doussal, V.; Voigt, J.J. 1999: Quality challenge for immunohistochemistry: example of the ERBB-2 status in breast cancer. Group for Evaluation of Prognostic Factors in Immunohistochemistry in Breast Cancer (GEFPICS) Annales de Pathologie 19(4): 280-282
Balbi, G.; Monteverde, A.; Passaro, M.; Cassese, E.; Landino, I.; Visconti, S. 2006: Vascular endothelial growth factor (VEGF): can we use it as prognostic factor in endometrial cancer? Minerva Ginecologica 58(5): 411-415
Watanabe, K.; Kawabata, K.; Ozaki, S.; Fujita, H.; Kojima, Y.; Tsuda, H. 2000: Bel-2 as a prognostic factor of breast cancers Nihon Rinsho. Japanese Journal of Clinical Medicine 58 Suppl: 423-428
Gebauer, G.; Jäger, W.; Lang, N. 1998: mRNA expression of components of the insulin-like growth factor system in breast cancer cell lines, tissues, and metastatic breast cancer cells Anticancer Research 18(2a): 1191-1195
Borg, A.; Zhang, Q.X.; Alm, P.; Olsson, H.; Sellberg, G. 1992: The retinoblastoma gene in breast cancer: allele loss is not correlated with loss of gene protein expression Cancer Research 52(10): 2991-2994